I did not say you were against it, I said that would be a disastrous business for the company at this time and Flaskworks belongs to NWBO, not any other company, it is a competitive advantage. It is for dendritic cell manufacturing and this company currently has a huge lead in that area. Why would they accelerate lots of companies to compete with them in a high profit area with a low profit, easily copied product?
It’s a terrible business strategy. I get that you were an engineer and you seem to get more excited by machinery than the drug itself, but DCVax-L took decades to get through clinical trials. The company did not do all of that to then sell easily copied machinery at low margin and junk the dendritic cell cancer vaccine business.
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
